ClinicalTrials.gg
RecruitingNCT07213817Updated Oct 1, 2026

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

A Phase 1/2 interventional study of IPN60300 in Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Ipsen. Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Ipsen · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 1, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
473rd of 1,864
114 · median 43
Started
2025
with 84 others
Phase 1/2
267 of 2,055
63 open now
Primary completion
2028-10
later than 424 of 541 live
Registered
1,976th of 2,055
by date

Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 473rd largest by planned enrollment of the 1,864 interventional ones that give a count, is one of 85 that started in 2025, is one of 267 in phase 1/2, reaches primary completion later than 424 of the 541 other live ones, and was the 1,976th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,055 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection.

Study Phases:

  • Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose).
  • Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance).

Study Periods:

Screening: Up to 28 days before first IPN60300 injection to determine eligibility.

Treatment: Starts with the first dose of IPN60300 and continues until it needs to be stopped due to harmful effects, the disease getting worse, or if the participant decides to stop taking part in the study, the investigator's decision to stop treatment, death or the study is terminated early by the sponsor.

Participants will undergo blood tests, urine collections, physical examinations, and clinical evaluations.

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 years of age, at the time of signing the .
  • Participants with or cytologically documented, locally advanced, or solid tumors, that or were refractory after being previously treated with standard of care therapy; or for which there is no available established therapy; or standard therapy is or not deemed appropriate by the treating investigator.
  • Participants must have per (RECIST) version 1.1.
  • (ECOG) performance status of 0 to 1.
  • Male and female participants use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Adequate bone marrow function within 7 days before first dose of study intervention,
  • Adequate renal function within 7 days before first dose of study intervention,
  • Adequate hepatic function or laboratory abnormalities indicating hepatic injury within 7 days before first dose of study intervention,
  • or international normalised ratio (INR) ≤1.5 × .
  • At the time of screening, a tumour tissue specimen is required for enrolment into the dose escalation and dose optimisation portions of the study for retrospective central laboratory determination.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Have a of more than 3 months for disease-related mortality, as evaluated by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known second either progressing or requiring active treatment within the last 2 years prior to first dose of study intervention.
  • Residual toxicity from prior anticancer therapy that are version 5.0 Grade 2 or higher. Stable chronic Grade 2 toxicities from previous treatments may be eligible per the judgement of investigator.
  • History of major surgery within 4 weeks prior to the first dose of study intervention.
  • Previous solid organ transplantation.
  • Pre-existing, acute or chronic severe corneal disorders, sequelae from severe corneal disorders, or a history of corneal transplantation.
  • Active or with exception to asymptomatic and treated brain metastases (i.e. no neurological symptoms, no requirements for and lesions \<1.5 cm), which are stable and not expected to become symptomatic in the next 3 months in the opinion of the investigator.
  • History of stroke or significant cerebrovascular disease (ie, ) within 6 months prior to initiation of study intervention.
  • History of cardiac disease within 6 months prior to the initiation of study intervention, including but not limited to unstable angina, acute myocardial infarction, endoscopic or open-heart cardiac surgery, or heart failure classified as Grade 2 or higher.
  • History of clinically significant respiratory disease within 6 months prior to the initiation of study intervention, including severe or asthma.
  • History of noninfectious interstitial lung disease (ILD)/pneumonitis/radiation pneumonitis that required steroids or has current ILD/pneumonitis.
  • Clinically significant gastrointestinal disorder including bleeding, occlusion, diarrhoea >Grade 1, malabsorption syndrome, ulcerative colitis, inflammatory bowel disease or partial bowel obstruction.
  • Any evidence of severe active infection or inflammatory condition.
  • Significant concurrent, uncontrolled medical condition that would put participants at unacceptable risk from study participation or preclude them from complying with study procedures as per investigator assessment, including, but not limited to renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
  • Participants with uncontrolled (HIV). HIV infected participants are eligible if they meet criteria described in the protocol.
  • Known active infection with virus (HBV) OR virus (HCV). Participants are eligible if they meet criteria described in the protocol.
  • Ongoing therapy, including systemic corticosteroids. NOTE: Physiologic replacement or use of topical or inhaled corticosteroids are allowed.
  • Concurrent participation in another therapeutic treatment trial, previous participation should respect the minimum of 5 half-lives or 4 weeks before the study intervention initiation (whichever is shorter).
  • Participants accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.
  • For French participants only: participants are under court protection, not affiliated to a social security system or protected adults.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
114 participants (estimated)

Study arms

  • Experimental
    Phase Ia: Dose escalation

    IPN60300 will be administered at assigned dose level.

    Biological: IPN60300

  • Experimental
    Phase Ib : Dose optimisation

    Participants will be randomised to one of the two doses of interest.

    Biological: IPN60300

Interventions

  • BiologicalIPN60300

    IPN60300 will be administered at assigned dose level.

06

What researchers measure

Primary outcomes

  1. Phase Ia: Percentage of participants with dose limiting toxicity (DLT)

    Time frame: within 21 days following study drug administration.

  2. Phase Ia and Ib: Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TE SAEs).

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is an AE for which the start date is on or after the date that the intervention began or it was present prior to receiving the intervention but the intensity increased during the active phase of the study.

    Time frame: From the first IPN60300 administration until 30 days after the last dose

  3. Phase Ib: Objective response rate (ORR)

    ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as determined by investigator per RECIST version 1.1

    Time frame: At end of study (up to approximately 3 years )

Secondary outcomes

  1. Phase Ia: Time to maximum observed drug concentration (tmax) of IPN60300 after single and multiple doses of IPN60300

    Time frame: within 21 days following study drug administration

  2. Phase Ia: Maximum observed drug concentration (cmax) of IPN60300 after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration

  3. Phase Ia: Area under the plasma concentration time curve over one dosing interval (AUCtau) of IPN60300 after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration

  4. Phase Ia: Tmax of Total Antibody after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration.

  5. Phase Ia: Cmax of Total Antibody after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration.

  6. Phase Ia: AUCtau of Total Antibody after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration.

  7. Phase Ia: Tmax of free toxin after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration.

  8. Phase Ia: Cmax of free toxin after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration.

  9. Phase Ia: AUCtau of free toxin after single and multiple doses of IPN60300

    Time frame: Within 21 days following study drug administration.

  10. Phase Ia and Ib: Percentage of Treatment-Emergent Anti-Drug Antibodies (ADA), Including Binding and Neutralizing Antibodies.

    Time frame: Prior study drug administration until the End of Treatment (EoT) visit (approximately up to 3 years

  11. Phase Ia: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with BOR of CR or PR, as determined by investigator per RECIST version 1.1

    Time frame: At end of study (up to approximately 3 years)

  12. Phase Ib: Duration of response (DoR)

    DoR is defined as the time from the first documented evidence of CR or PR until progressive disease, as determined by investigator per RECIST version 1.1, or death from any cause, whichever occurs first

    Time frame: At end of study (up to approximately 3 years)

  13. Phase Ib: Progression-free survival (PFS)

    PFS is defined as the time from the date of first IPN60300 administration to the date of the first documented disease progression, as determined by investigator per RECIST version 1.1, or death due to any cause, whichever occurs first

    Time frame: At end of study (up to approximately 3 years)

  14. Phase Ib: Disease control rate (DCR)

    DCR is defined as the percentage of participants with BOR of CR, PR or stable disease (SD), as determined by investigator per RECIST version 1.1

    Time frame: At end of study (up to approximately 3 years)

07

Study locations

10 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.

Of 127 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 34 months is below that.

Counting every sponsor, half of 213 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 9, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
NEXT Quiron-Barcelona is now Active, not recruiting
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    NEXT Quiron-Barcelona is now Active, not recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213817
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Dec 5, 2025
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
See e mail
Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion